Educational & Research Use Only. Not medical advice. Compounds are research-grade and not FDA-approved unless explicitly noted.
01
Section 01 · 11 compounds

Incretin & Metabolic Receptor Agonists

Restoring appetite signaling and energy regulation — the most rapidly evolving frontier in modern metabolic research.

Home/ Sections/ Incretin & Metabolic Receptor Agonists

Metabolic health is the rhythm by which the body turns food into energy, stores what it should, and burns what it must. Modern life knocks that sequence off kilter — incretin hormones (GLP-1, GIP, glucagon) are the body's metabolic conductors, and the compounds in this section are agonists that turn the volume back up on signals gone quiet.

Click any peptide below to expand. Each entry covers what it is, what it's being studied to do, why it matters, potential impact, and common research pairings, with quick facts in the sidebar.

31-Amino Acid Peptide · FDA Approved

Semaglutide is a 31-amino-acid GLP-1 receptor agonist engineered for prolonged activity. Depending on the FDA-approved product and formulation, semaglutide is used for type 2 diabetes, chronic weight management, cardiovascular-risk reduction in selected adults with cardiovascular disease and overweight or obesity, and noncirrhotic MASH with moderate-to-advanced fibrosis.

Plain-Language PictureImagine the "I'm full" signal in your brain as a radio station. Semaglutide doesn't change the song — it just turns up the volume on the music your body was always supposed to be hearing.

What It's Being Studied To Do

  • Reduce appetite by amplifying natural fullness signals — quieting the persistent "food noise" of cravings
  • Extend the duration of post-meal satiety by slowing gastric emptying
  • Stabilize blood glucose to avoid spikes and crashes
  • Improve cellular insulin sensitivity
  • Support the body's natural fat-burning processes — without adding new functions, simply amplifying existing ones

Why This Matters

Many people today live in a fog of constant cravings and energy dips because modern diets and lifestyles dull the body's natural fullness cues. Strengthening GLP-1 signaling helps researchers understand how to bring appetite back into alignment with actual energy needs — restoring the body's designed rhythm of hunger, satisfaction, and steady fuel use.

Potential Impact Being Explored

Reductions in body fat, quieter "food noise," steadier blood sugar, lower markers of cardiovascular and metabolic stress, and more stable daily energy. Backed by extensive human clinical trial data.

Common Research Pairings

AOD-9604 · focused fat metabolismL-Carnitine · fatty acid transportMOTS-C · mitochondrial efficiencySS-31 · mitochondrial protection

39-Amino Acid Peptide · FDA Approved · Second Generation

Tirzepatide is a 39-amino-acid dual GIP and GLP-1 receptor agonist. FDA-approved products containing tirzepatide are used for type 2 diabetes and chronic weight management; Zepbound is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity. Its dual-receptor pharmacology distinguishes it from single-receptor GLP-1 agonists.

Plain-Language PictureGLP-1 manages the front of the house — when to eat, when to stop. GIP manages the back — how to use what came in. Tirzepatide hires both managers at once, and the kitchen runs smoother.

What It's Being Studied To Do

  • Strengthen the brain's "satisfied" signal more powerfully than single-receptor compounds
  • Slow gastric emptying for prolonged fullness
  • Improve insulin sensitivity so cells absorb and use glucose efficiently
  • Promote significant fat loss — often greater than single-pathway compounds in trials
  • Influence broader metabolic markers: cholesterol, inflammation, liver function

Why This Matters

Metabolic challenges rarely come from one cause. Insulin resistance, poor nutrient absorption, and imbalanced hormones all stack on top of each other. By amplifying two of the body's own incretin hormones simultaneously, Tirzepatide aligns with restoring multi-layered hormonal coordination — supporting steadier vitality and reducing the metabolic burden many people carry without realizing.

Potential Impact Being Explored

Substantial reductions in body weight and improvements in glycemic and cardiometabolic measures are supported by large human clinical-trial programs. Weight loss includes both fat and lean tissue, so “muscle preservation” should not be treated as an automatic effect.

Common Research Pairings

AOD-9604 · fat-metabolism signalingMOTS-C · mitochondrial adaptation5-Amino-1MQ · cellular energy partitioningL-Carnitine · fatty acid utilization

Dual GLP-1 / Glucagon Agonist · Phase 3 Results Reported 2026 · Investigational

Where Tirzepatide pairs intake control with insulin support, Survodutide pairs intake control with energy expenditure. This 39-amino-acid peptide hits two receptors: GLP-1 for fullness, and the glucagon receptor for telling the body to release and burn stored energy — particularly fat held in the liver and adipose tissue.

What It's Being Studied To Do

  • Reduce appetite and delay digestion via GLP-1
  • Increase energy expenditure and fat mobilization via glucagon
  • Improve blood sugar control
  • Mobilize fat from storage sites including the liver

Why This Matters

Metabolic problems often come from a two-sided imbalance: too much intake on one side, too little burning on the other. Survodutide research focuses on fine-tuning both sides of the scale — exploring how to support the body's ability to use energy efficiently rather than accumulate it.

Potential Impact Being Explored

Notable fat reduction, signals for higher metabolic rate, improved insulin markers, greater fuel-use flexibility, and potential benefits for liver health (especially fatty liver markers).

Common Research Pairings

MOTS-C · cellular energy adaptationL-Carnitine · fat transportSS-31 · mitochondrial supportAOD-9604 · targeted fat signaling

39-Amino Acid Peptide · GLP-1 / GIP / Glucagon · Pivotal Phase 3 Results Reported

Retatrutide is the next-generation flagship of metabolic research — a 39-amino-acid peptide that activates three hormone receptors at once: GLP-1, GIP, and glucagon. By engaging all three pathways simultaneously, it pursues what researchers describe as a balanced "intake → process → burn" model of metabolic coordination.

Plain-Language PictureThree managers, one mission: GLP-1 controls intake, GIP refines processing, glucagon ramps up output. Together they form a metabolic triangle that addresses every side of the energy equation.

What It's Being Studied To Do

  • Reduce appetite through stronger fullness signals
  • Slow gastric emptying so meals feel more satisfying for longer
  • Improve blood sugar regulation and insulin sensitivity
  • Increase energy expenditure by encouraging the body to burn stored fuels
  • Promote substantial fat reduction while preserving lean muscle
  • Support metabolic flexibility — the ability to switch between burning carbs, fats, or protein

Why This Matters

Modern lifestyles disrupt multiple metabolic systems at once — sedentary habits, high-sugar diets, and chronic stress create a state of metabolic disarray: constant hunger, inefficient fat storage, insulin resistance, low energy. Retatrutide's triple-pathway approach aligns with the idea of restoring overlapping systems back into harmony, not just managing one symptom at a time.

Potential Impact Being Explored

Pivotal Phase 3 trials reported substantial mean weight reduction and improvements in glycemic measures in studied populations. Retatrutide remains investigational; regulatory approval and long-term benefit-risk assessment are still pending, and claims about preferential muscle preservation should not be assumed from weight-loss results alone.

Common Research Pairings

AOD-9604 · supplementary fat signalingMOTS-C · mitochondrial adaptation5-Amino-1MQ · cellular partitioningSS-31 · mitochondrial protectionL-Carnitine · fatty acid transport

Dual GLP-1 / Glucagon Agonist · Approved in China · Not FDA Approved

Mazdutide is a synthetic dual agonist derived structurally from oxyntomodulin, a natural gut hormone. Engineered for once-weekly dosing, it activates both the GLP-1 and glucagon receptors — pairing intake reduction with increased energy output. China’s NMPA approved mazdutide in 2025 for chronic weight management and for glycemic control in adults with type 2 diabetes. It is not FDA-approved in the United States.

What It's Being Studied To Do

  • Powerfully reduce appetite and slow gastric emptying via GLP-1 activation
  • Increase energy expenditure and fat mobilization via glucagon receptor activation
  • Deliver robust weight loss while preserving lean muscle mass
  • Improve glycemic control and insulin sensitivity
  • Support favorable cardiometabolic markers

Why This Matters

Many people face a dual challenge: hunger signals that won't quiet, and a metabolism that won't burn efficiently. Mazdutide's research explores addressing both ends of the energy equation at once — helping the body reclaim its original, balanced design for weight regulation and steady vitality.

Potential Impact Being Explored

Clinical trials supported regulatory approvals in China for weight management and type 2 diabetes. The approval status is jurisdiction-specific, and the compound remains unapproved by the U.S. FDA.

Common Research Pairings

MOTS-C · mitochondrial supportSS-31 · energy stabilityAOD-9604 · fat signalingL-Carnitine · fat transport

Complementary Pathway to GLP-1

Cagrilintide approaches metabolic regulation from a different angle. Rather than mimicking incretin hormones, it mimics amylin — a hormone released alongside insulin from the pancreas that regulates appetite and post-meal glucose. Where GLP-1 signaling is one voice in the chorus, amylin signaling is another. Pair them and you get harmony.

What It's Being Studied To Do

  • Reduce hunger through amylin pathway activation
  • Slow stomach emptying complementarily to GLP-1
  • Improve after-meal blood sugar control
  • Quiet "food noise" and persistent food thoughts
  • Support sustainable weight management

Why This Matters

Appetite isn't a single signal — it's layered. One hormonal voice alone may not be enough to bring eating cues back into balance. Amylin research adds another harmony to the song, exploring fuller appetite regulation that no single pathway can deliver.

Potential Impact Being Explored

Stronger hunger control, improved fullness signaling, enhanced effects when paired with GLPs, and stable glucose handling.

Common Research Pairings

Retatrutide · combined appetite controlTirzepatide · multi-pathway synergySemaglutide · GLP-1 + amylin pairingMOTS-C · adaptation support

Exercise Mimetic · 16 Amino Acids · Encoded Within Mitochondria

MOTS-C may be one of the most quietly revolutionary discoveries in mitochondrial biology. It's a 16-amino-acid peptide encoded directly within the mitochondrial genome — the tiny "power plant" DNA inside every cell. Unlike most peptides, which are made in the nucleus, MOTS-C originates from the mitochondria themselves. It functions as a signaling molecule that lets mitochondria talk back to the rest of the cell — even to the nucleus — coordinating energy demands, stress, and adaptation.

The "Exercise Pill" ConversationMOTS-C is often called an exercise mimetic — meaning it triggers many of the same beneficial cellular adaptations that endurance training produces, even without the workout. Not a replacement for movement, but a window into why movement works at the molecular level.

What It's Being Studied To Do

  • Activate AMPK, the body's metabolic master switch — boosting energy production, fat oxidation, and glucose uptake without insulin spikes
  • Enhance mitochondrial biogenesis (creating more efficient mitochondria) and respiration (better ATP output)
  • Improve metabolic flexibility — helping cells switch seamlessly between burning carbs, fats, or other fuels
  • Reduce inflammation and oxidative stress
  • Support insulin sensitivity and glucose homeostasis
  • Protect against age-related metabolic decline, muscle atrophy, and insulin resistance

Why This Matters

Mitochondria are the engines of life — they produce energy, manage stress, and signal for repair. When they weaken with age, poor diet, inactivity, or chronic stress, you feel tired, gain fat more easily, lose muscle resilience, and face higher risks of metabolic disease. MOTS-C research is thrilling because it taps into the body's own mitochondrial language to help restore efficient energy use, better fuel switching, and cellular vitality.

Potential Impact Being Explored

Dramatically improved endurance and physical performance (older mice ran significantly farther after treatment). Enhanced fat loss and metabolic efficiency. Protection against age-related decline in heart, liver, and brain models. Delayed senescence in pancreatic cells. Lower circulating MOTS-C levels seen in T2D, obesity, and aging populations — suggesting restoration could be transformative. Often described as a game-changer for energy, body composition, and resilience.

Common Research Pairings

Retatrutide / Tirzepatide / Semaglutide · appetite + energy synergySS-31 · structural mitochondrial protectionL-Carnitine · fatty acid transportNAD+ · upstream energy + DNA repairAOD-9604 · targeted fat signaling

Targeted Fat Metabolism · No Broad Hormonal Effects

AOD-9604 is a clever piece of molecular engineering: a 16-amino-acid synthetic fragment derived from the C-terminal region of human growth hormone (amino acids 176–191), with an added tyrosine for stability. The point of the fragment? To keep the fat-metabolism signaling of growth hormone while leaving behind the broad anabolic effects — no IGF-1 spikes, no systemic growth pathways activated. Just the fat-burning conversation, isolated.

What It's Being Studied To Do

  • Promote lipolysis (fat breakdown) in adipose tissue
  • Support fat oxidation without affecting appetite or broad hormones
  • Inhibit lipogenesis (formation of new fat cells)
  • Enhance energy expenditure in obese models
  • Possibly support cartilage and joint health (some preclinical contexts)
  • Interact with beta-adrenergic pathways to increase glycerol release and fatty acid mobilization

Why This Matters

Stubborn fat isn't always about calories. Often it's about disrupted signaling — the body forgetting how to release stored fuel. AOD-9604 research investigates how a focused fragment of natural growth hormone might help restore efficient fat utilization at the cellular level, without unnecessary systemic effects.

Potential Impact Being Explored

Preclinical studies in obese mice and rats show reductions in body fat, increased lipolytic activity, and improved body weight without insulin resistance changes. Human clinical data remains limited and mixed — some studies show modest benefits, others show no significant weight loss at tested doses.

Common Research Pairings

Semaglutide / Tirzepatide / Retatrutide · appetite + fat signalingL-Carnitine · fatty acid transportMOTS-C · mitochondrial supportSS-31 · mitochondrial stability

Endurance Mimetic · Saint Louis University Discovery

Despite living in this guide alongside peptides, SLU-PP-332 is a small molecule, not a peptide. It earns its place because it speaks the same metabolic language. Developed by researchers at Saint Louis University (hence "SLU"), it selectively activates PPARδ — a nuclear receptor central to fatty acid metabolism and endurance signaling.

What It's Being Studied To Do

  • Activate PPARδ to drive endurance signaling and mitochondrial biogenesis
  • Improve lipid metabolism and fat oxidation
  • Enhance metabolic flexibility (fuel-source switching)
  • Mimic exercise-induced pathways without physical activity
  • Support insulin sensitivity and reduce inflammation
  • Provide potential neuroprotection in metabolic brain models

Why This Matters

Exercise rewires metabolism in profound ways, but sedentary lifestyles or physical limitations cut off those benefits. SLU-PP-332 research explores chemically activating these innate adaptive pathways — helping restore efficient fuel handling and endurance as part of the body's original design for movement and resilience.

Potential Impact Being Explored

Preclinical studies in mice show increased running endurance, higher fat-burning rates, improved mitochondrial function in muscle and brain, better glucose tolerance, and reduced inflammation markers — frequently described as an "exercise pill" for metabolic and aging research.

Common Research Pairings

MOTS-C · mitochondrial adaptationL-Carnitine · fatty acid utilizationRetatrutide · intake + expenditureNAD+ · broader energy support

Methionine · Inositol · Choline · B Vitamins

Lipo-C isn't a peptide — it's a blend. Specifically, a combination of lipotropic nutrients: methionine, inositol, choline, and B vitamins (typically B6 and B12). Lipotropics are compounds that help the body break down fat, transport it through the liver, and clear it efficiently. Lipo-C is included here because metabolic research increasingly recognizes that liver health and methylation status are inseparable from how the body handles fat and energy.

What It's Being Studied To Do

  • Support fat metabolism by aiding lipid breakdown and transport
  • Enhance methylation processes (methionine for DNA and epigenetic regulation)
  • Promote liver detoxification and bile production (choline and inositol)
  • Improve nutrient-driven metabolic efficiency
  • Reduce fatty liver markers in overloaded models

Why This Matters

The liver is the body's central processing hub — fats, toxins, and nutrients all pass through it. When the liver is overburdened by poor diet or stress, metabolism slows, fat accumulates, and energy drops. Lipo-C research explores how natural nutrients can support efficient liver coordination — restoring the body's designed system for clean, balanced processing.

Potential Impact Being Explored

Preclinical and anecdotal studies suggest improved fat mobilization, enhanced detox markers (reduced liver enzymes), better nutrient absorption, and support during metabolic reset phases — commonly discussed in weight management and liver health contexts.

Common Research Pairings

Semaglutide / Tirzepatide · liver support during fat lossL-Carnitine · fatty acid utilizationMOTS-C / SS-31 · mitochondrial synergy

Cellular Energy Partitioning · Small Molecule

This compound asks a deeper question than most: what if the problem isn't appetite or calories, but the way cells decide what to do with energy once it arrives? 5-Amino-1MQ targets nicotinamide N-methyltransferase (NNMT), an enzyme that influences cellular energy regulation. NNMT consumes resources that could otherwise sustain NAD+ levels — and when NNMT is too active, cells drift toward storing fuel as fat instead of burning it.

What It's Being Studied To Do

  • Reduce excess fat accumulation signaling in adipocytes (decreasing lipogenesis and adipocyte size)
  • Improve insulin sensitivity and glucose handling
  • Influence intracellular energy partitioning — encouraging cells to burn fuel rather than store it
  • Support metabolic efficiency by preserving NAD+ (a key cofactor for energy production and sirtuin activation)
  • Promote fat oxidation and reduce white adipose tissue mass in diet-induced obesity models
  • Indirectly enhance mitochondrial function via better NAD+ availability

Why This Matters

Metabolic dysfunction isn't always about willpower or calories — sometimes it's deeper, at the cellular level, where cells inefficiently store energy as fat instead of using it. NNMT overactivity is linked to obesity, insulin resistance, and age-related metabolic slowdown. 5-Amino-1MQ research explores how blocking this enzyme might help restore proper energy decisions inside cells.

Potential Impact Being Explored

Significant body fat reduction, enhanced insulin sensitivity, better cellular fuel utilization, preservation of NAD+ levels (tying into sirtuin activation and longevity), and reversal of diet-induced obesity markers in short studies — 11-day treatments normalized weight and fat mass in mice.

Common Research Pairings

Semaglutide / Tirzepatide / Retatrutide · intracellular + appetiteMOTS-C · mitochondrial flexibilityAOD-9604 · fat signalingL-Carnitine · fatty acid utilization
02 · Repair, Regeneration & Structural Recovery →